Saturday - October 25, 2025
Johnson & Johnson Receives U.S. FDA Priority Review for AKEEGA in BRCA-mutated Metastatic Castration-sensitive Prostate Cancer
October 17, 2025
RARITAN, New Jersey, Oct. 17 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:

* * *

Johnson & Johnson receives U.S. FDA Priority Review for AKEEGA (niraparib and abiraterone acetate dual-action tablet) in BRCA-mutated metastatic castration-sensitive prostate cancer

HORSHAM, PA - The U.S. Food and Drug Administration (FDA) granted Priority Review to Johnso . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products